Anna Paola Savoldi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Paola Savoldi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Martino Doniselli
Neuroradiology Unit Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
2 shared publications - Alessandra Erbetta
Neuroradiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
1 shared publication - Andrea Stabile
Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
1 shared publication - Angelo Del Sole
Department of Health Sciences, University of Milan, Milan, Italy
1 shared publication - Annalisa Parente
Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
1 shared publication - Carlo Antozzi
Immunotherapy and Apheresis Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 5 March 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 50, 103986
Pediatric anti-NMDAR encephalitis: Neuroradiological presentation, cognitive outcome and volumetric MRI analysis
- 5 March 2026
- Published by Elsevier in NeuroImage: Clinical
- Vol. 50, 103986
Open AccessPediatric anti-NMDAR encephalitis: Neuroradiological presentation, cognitive outcome and volumetric MRI analysis
- 26 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (10) , 5437-5445
Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy
Introduction Autoimmune polyglandular syndromes (APS) encompass a broad spectrum of disorders. APS III is characterized by autoimmune thyroiditis (AT) plus any autoimmune disorder, excluding Addison's disease. Methods and results This study explores the link between GAD65 related-temporal lobe epilepsy (GAD-TLE) and APS III. We retrospectively analyzed 29 GAD-TLE patients. Eighteen patients (62%) experienced at least one autoimmune disease, and ten patients (56%) fulfilled diagnostic criteria for APS III. In addition to AT and GAD-TLE, five patients had type 1 diabetes mellitus, one patient had latent autoimmune diabetes in adulthood, one autoimmune alopecia, one pernicious anemia, one had celiac disease and one patient had autoimmune alopecia, vitiligo, autoimmune atrophic gastritis and psoriasis. Approximately 35 years after the onset of the first disease, the probability of having the second disorder is over 80%. In our cohort, GAD65 antibodies are more frequently linked to AT than to type 1 diabetes mellitus, despite their well-known association. Conclusion Our data suggests that GAD65-TLE may share a common pathophysiology and should be included among APS-III diagnostic criteria. These insights support the need for rigorous, multidisciplinary monitoring to prevent delays in diagnosis and treatment. This work enhances understanding of APS complexity and informs targeted management strategies for patients with overlapping endocrine and neurological autoimmune disorders.
- 26 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (10) , 5437-5445
Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy
Introduction Autoimmune polyglandular syndromes (APS) encompass a broad spectrum of disorders. APS III is characterized by autoimmune thyroiditis (AT) plus any autoimmune disorder, excluding Addison's disease. Methods and results This study explores the link between GAD65 related-temporal lobe epilepsy (GAD-TLE) and APS III. We retrospectively analyzed 29 GAD-TLE patients. Eighteen patients (62%) experienced at least one autoimmune disease, and ten patients (56%) fulfilled diagnostic criteria for APS III. In addition to AT and GAD-TLE, five patients had type 1 diabetes mellitus, one patient had latent autoimmune diabetes in adulthood, one autoimmune alopecia, one pernicious anemia, one had celiac disease and one patient had autoimmune alopecia, vitiligo, autoimmune atrophic gastritis and psoriasis. Approximately 35 years after the onset of the first disease, the probability of having the second disorder is over 80%. In our cohort, GAD65 antibodies are more frequently linked to AT than to type 1 diabetes mellitus, despite their well-known association. Conclusion Our data suggests that GAD65-TLE may share a common pathophysiology and should be included among APS-III diagnostic criteria. These insights support the need for rigorous, multidisciplinary monitoring to prevent delays in diagnosis and treatment. This work enhances understanding of APS complexity and informs targeted management strategies for patients with overlapping endocrine and neurological autoimmune disorders.